Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Investigating the MAIT cell- Microbiome Relationship in Pancreatic Cancer Liver Metastasis

Award Number: F30CA291094
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 04/29/2024
PERIOD OF PERFORMANCE END DATE: 04/28/2028

Group Awards By:

View Award Description

Investigating the MAIT cell- Microbiome Relationship in Pancreatic Cancer Liver Metastasis - Project Summary/Abstract Pancreatic cancer liver metastasis (PCLM) is present in 50% of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) and has a median survival of <6 months. Recent studies in mice found that modulating the gut microbiome can reduce PCLM tumor burden by augmenting anti-tumor immunity. The gut microbiome is constantly producing antigens the travel to the liver. This suggests that gut microbiome modulation induces PCLM anti-tumor immunity by altering the antigens presented in the liver, however the mechanism is unclear. Mucosal Associate Invariant T (MAIT) cells are an innate subset of T cells which can be classified into two phenotypes: an “anti-tumor” MAIT1 or a “pro-tumor” MAIT17 phenotype. MAIT cells closely interact with gut microbiome derived antigens through their activation mechanisms, and this can shift their phenotype. Direct activation leads to a MAIT17 phenotype, involving interactions with microbial riboflavin synthesis pathway- derived metabolite ligands presented on antigen presenting cells (APCs) via MHCI related protein (MR1). Indirect activation induces a MAIT1 phenotype by stimulating MAIT cell IL-12 and IL-18 receptors15. These cytokines are released by APCs upon stimulation by microbial-produced ligands. Consequently, the goal of this project is to harness the gut microbiome to modulate MAIT cell phenotypes towards treatment of PCLM. Preliminary data suggests that MR1 expression is upregulated in the PCLM tumor microenvironment (TME) which promotes a pro-tumor MAIT17 phenotype via direct MAIT cell activation. This suggests an abundance of gut microbiome derived MR1 ligands in the PCLM TME. In Aim 1, we hypothesize that gut microbiome dysregulation provides MR1 ligands to the PCLM TME which promotes PCLM via inducing a MAIT 17 phenotype. We will test this by 1) Correlating the abundance of MR1 ligands in the PCLM TME with the MAIT17 phenotype; 2) Determining the gut microbiome composition of mice with PCLM by shotgun metagenomic sequencings; 3) characterizing how a MAIT17 phenotype promotes PCLM tumor burden by single cell RNA sequencing. Further preliminary data shows that promoting a MAIT1 phenotype reduces PCLM tumor burden. Also, gut microbiome depletion by antibiotic treatment (ABX) promotes a MAIT1 phenotype, which likely promotes anti- tumor TH1 cells, in the liver. In Aim 2, we hypothesize that ABX reduces MR1 ligands in the PCLM TME which promotes a MAIT1 phenotype and anti-tumor immunity. We will test this by 1) Investigating the MAIT cell phenotype in PCLM+ABX mice and validating by fecal microbiome transfers; 2) Determining the gut microbiome composition following ABX; 3) Probing anti-tumor immunity in the PCLM+ABX TME by imaging mass cytometry. These studies will identify MAIT cells as the missing link between the gut microbiome and anti-tumor immunity and will affect how PCLM and other liver conditions are treated. This research plan and my outlined training plan are supported by exceptional institutional support and by an exceptional mentorship team. This will provide an unmatched multidisciplinary research and clinical training experience that perfectly aligns with my career goals.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $55,114 )
2026	2026	WAYNE STATE UNIVERSITY	5700 CASS AVE STE 4900	DETROIT	MI	48202	WAYNE	USA	Cancer Research Manpower	000	3	4/21/2026	NON-COMPETING CONTINUATION	$55,114
														Subtotal = $55,114

Issue Date FY: 2025 ( Subtotal = $49,763 )
2025	2025	WAYNE STATE UNIVERSITY	5700 CASS AVE STE 4900	DETROIT	MI	48202	WAYNE	USA	Cancer Research Manpower	001	2	5/29/2025	NON-COMPETING CONTINUATION	$564
2025	2025	WAYNE STATE UNIVERSITY	5700 CASS AVE STE 4900	DETROIT	MI	48202	WAYNE	USA	Cancer Research Manpower	000	2	4/11/2025	NON-COMPETING CONTINUATION	$49,199
														Subtotal = $49,763

Issue Date FY: 2024 ( Subtotal = $49,199 )
2024	2024	WAYNE STATE UNIVERSITY	5700 CASS AVE STE 4900	DETROIT	MI	48202	WAYNE	USA	Cancer Research Manpower	000	1	4/9/2024	NEW	$47,919
2024	2024	WAYNE STATE UNIVERSITY	5700 CASS AVE STE 4900	DETROIT	MI	48202	WAYNE	USA	Cancer Research Manpower	002	1	5/7/2024	NEW	$1,280
2024	2024	WAYNE STATE UNIVERSITY	5700 CASS AVE STE 4900	DETROIT	MI	48202	WAYNE	USA	Cancer Research Manpower	001	1	4/9/2024	NEW	$0
														Subtotal = $49,199

Grand Total All Awards = $154,076

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Investigating the MAIT cell- Microbiome Relationship in Pancreatic Cancer Liver Metastasis

Award Number: F30CA291094

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 04/29/2024

PERIOD OF PERFORMANCE END DATE: 04/28/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer